Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eplerenone Sandoz Inc., USA · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Eplerenone 50mg Tablets |
| 2 | ACTIVE_COMPARATOR | INSPRA 50mg Tablets |
| Name | Type | Description |
|---|---|---|
| Eplerenone 50 mg Tablets Sandoz Inc., USA | DRUG | - |
| Inspra 50 mg Tablets GD Searle LLC, USA | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Eplerenone Sandoz Inc., USA is a small molecule being developed for hypertension, a cardiovascular condition. It is currently in Phase 1 clinical development as an investigational drug. Two Phase 1 trials have been completed, each enrolling 60 healthy volunteers to study the bioavailability of the 50 mg tablet formulation.
Eplerenone Sandoz Inc., USA is being developed by Novartis AG, which trades under the ticker NVS. The drug is a small molecule intended for the treatment of hypertension. It is currently in Phase 1 clinical development, with two completed bioavailability studies.
Eplerenone Sandoz Inc., USA is in Phase 1 clinical development. Two Phase 1 trials have been completed, both focusing on the comparative bioavailability of the 50 mg tablet under fasting and fed conditions. The drug is investigational and has not been approved for hypertension.
Eplerenone Sandoz Inc., USA has two completed Phase 1 trials: NCT00865176, a comparative bioavailability study under fasting conditions, and NCT00865618, a comparative bioavailability study under fed conditions. Each trial enrolled 60 healthy volunteers aged 18 years and older, with a total enrollment of 120 participants.
Eplerenone Sandoz Inc., USA is a specific formulation of eplerenone, a small molecule being developed for hypertension. The name includes the developer and country, indicating it is a version of eplerenone. It is currently in Phase 1 clinical development, with two completed bioavailability studies.